MJA
MJA InSight
MJA Careers
Editorials

Challenges and opportunities for the Pharmaceutical Benefits Scheme

Philip M Clarke
Med J Aust 2012; 196 (3): 153-154.
doi:
10.5694/mja12.10092

Price disclosure will only go part of the way to achieving lower prices for generic drugs

Philip M Clarke, BEc, MEc, PhD, Professor of Health Economics
Centre for Health Policy, Programs and Economics, School of Population Health, University of Melbourne, Melbourne, VIC.
Article References: 
Reference Text: 
Senate Finance and Public Administration References Committee. The Government's administration of the Pharmaceutical Benefits Scheme. Canberra: Commonwealth of Australia, 2011. http://www.aph.gov.au/Senate/committee/fapa_ctte/pharma_benefits_scheme/report/report.pdf (accessed Feb 2012).
Reference Order: 
1
Reference Text: 
Clarke PM, Fitzgerald EM. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia. Med J Aust 2010; 192: 633-636.
Reference Order: 
2
PubMed ID: 
20528715
Reference Text: 
Australian Government and Medicines Australia. Memorandum of understanding. September 2010. http://www.pbs.gov.au/industry/useful-resources/memorandum/MOU-MA-Sep2010.pdf (accessed Jan 2012).
Reference Order: 
3
Reference Text: 
Medicare Australia. Explanation of PBS pricing. June 2011. Canberra: Australian Government, 2011. http://www.medicareaustralia.gov.au/provider/pubs/program/files/2526-explanation-of-pbs-pricing.pdf (accessed Feb 2012).
Reference Order: 
4
Reference Text: 
Australian Government Department of Health and Ageing. National Health (Weighted average disclosed price – main disclosure cycle) Determination 2011 (No. PB 80 of 2011). http://www.comlaw.gov.au/Details/F2011L02702 (accessed Jan 2012).
Reference Order: 
5
Reference Text: 
Clarke PM, Fitzgerald EM. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia [letter]. Med J Aust 2011; 194: 53-54.
Reference Order: 
6
Reference Text: 
Ontario Ministry of Health. Update ad: Ontario Drug Benefit Formulary/Comparative Drug Index No. 41. Effective January 19, 2012. http://www. health. gov.on.ca/english/providers/program/drugs/formulary/41_update _ad_20120111.pdf (accessed Jan 2012).
Reference Order: 
7
Reference Text: 
Pharmaceutical Management Agency (PHARMAC) (NZ). Notification: Approval of the listing of Dr Reddy’s brand of atorvastatin. 14 September 2011. http://www.pharmac.govt.nz/2011/09/14/2011-09%20Dr%20Reddy%27s% 20Atorvastatin%20notification.pdf (accessed Jan 2012).
Reference Order: 
8
Reference Text: 
Jackevicius CA, Chou MM, Ross JS, et al. Generic atorvastatin and health care costs. N Engl J Med 2012; 366: 201-204. Epub 2011 Dec 7.
Reference Order: 
9
PubMed ID: 
22149736
Reference Text: 
Health and Social Care Information Centre, National Health Service (UK). Prescription cost analysis, England – 2010. 27 April 2011. http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescription-cost-analysis-england--2010 (accessed Jan 2012).
Reference Order: 
10

The full contents of this page are only available to subscribers.